• Profile
Close

Patient-reported quality of life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy ± chemotherapy in the BC2001 phase III randomised controlled trial

European Urology Dec 19, 2019

Huddart RA, Hall E, Lewis R, et al. - In the present study, the researchers analyzed the impact of treatment on the health-related quality of life (HRQoL) of BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, candidates. Study participants included 458 UK individuals with T2-T4a N0 M0 transitional cell carcinoma of the bladder. Information was available for 331 and 204 candidates at baseline and for 192 and 114 at 12 months for the chemotherapy and radiotherapy comparisons, respectively. A significant proportion of patients record reductions in HRQoL immediately following (chemo)radiotherapy, which improves to baseline after 6 months. During long-term follow-up, two-thirds of patients report stable or improved HRQoL. There is no evidence of impairment caused by the addition of chemotherapy in HRQoL.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay